AR057579A1 - Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac) - Google Patents

Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)

Info

Publication number
AR057579A1
AR057579A1 ARP060104989A ARP060104989A AR057579A1 AR 057579 A1 AR057579 A1 AR 057579A1 AR P060104989 A ARP060104989 A AR P060104989A AR P060104989 A ARP060104989 A AR P060104989A AR 057579 A1 AR057579 A1 AR 057579A1
Authority
AR
Argentina
Prior art keywords
alkyl
aryl
substituted
independently selected
unsubstituted
Prior art date
Application number
ARP060104989A
Other languages
English (en)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of AR057579A1 publication Critical patent/AR057579A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Abstract

Se refiere a una clase de compuestos espirocíclicos sustituidos. Estos compuestos pueden inhibir la histona deacetilasa y son adecuadas para su uso en la induccion de forma selectiva de la diferenciacion terminal y de la detencion del crecimiento celular y/o apoptosis de células neoplásicas, inhibiendo de este modo la proliferacion de dichas células. De esta manera, los compuestos de la presente son utiles para tratar a un paciente que tiene un tumor caracterizado por la proliferacion de células neoplásicas. Los compuestos de la presente también pueden ser utiles en la prevencion y tratamiento de enfermedades mediadas por TRX, tales como enfermedades autoinmunes, alérgicas e inflamatorias, y en la prevencion y/o tratamiento de enfermedades del sistema nervioso central (SNC), tales como enfermedades neurodegenerativas. La presente también proporciona composiciones farmacéuticas que comprenden los compuestos de la presente y regímenes de dosificacion seguros de estas composiciones farmacéuticas, que son fáciles de seguir, y que dan como resultado una cantidad terapéuticamente eficaz de estos compuestos in vivo. Reivindicacion 1: Un compuesto, representado por la formula (1), en la que: A, B y D se seleccionan independientemente entre CR12; NR1a, C(O) y O; E se selecciona entre un enlace, CR12, NR1a, C(O) y O; donde al menos uno de A, B, D o E es CR12; y con la condicion de que cuando A es O, entonces E no es O; ôla línea de puntosö es un doble enlace opcional; ôel círculo Wö es un arilo o heteroarilo, opcionalmente sustituido con 1 a 3 sustituyentes seleccionados entre R7; ôel círculo Zö es un arilo o heteroarilo; R1 se selecciona independientemente entre hidrogeno, alquilo C1-6, (CR62)nR10, (CR62)nC(O)R4, (CR62)nC(O)OR4, (CR62)nC(O)R52, (CR62)nS(O)R4, (CR62)nOH y halo; R1a se selecciona independientemente entre hidrogeno, alquilo C1-6, (CR62)nR10, (CR62)nC(O)R4, (CR62)nC(O)OR4, (CR62)nC(O)NR52 o (CR62)nS(O)2R4; L1 se selecciona entre un enlace, -CR112-, -C(O)NR5-, -NR5C(O)- y -C(O)-; R3 se selecciona entre H, alquilo C1-6 sin sustituir o sustituido, arilo sin sustituir o sustituido, heteroarilo sin sustituir o sustituido, halo, CN, amida, carboxilo, alcoxi C1-7, haloalquilo C1- 7, haloalquiloxi C1-7, hidroxialquilo C1-7, alquenilo C1-7, alquinilo C1-7, alquilC1-7-C(=O)O-, alquilC1-7-C(=O)-, hidroxialcoxi, -NHSO2, -SO2NH, alquilC1-7-NHSO2-, alquilC1-7-SO2NH-, alquiloC1-7-sulfonilo, alquilC1-7-amino, dialquilC1-7-amino, y L2- R12; R4 se selecciona independientemente entre H, alquilo C1-6, arilo, y heterociclilo, donde alquilo, arilo o heterociclilo puede estar opcionalmente sustituido; R5 se selecciona independientemente entre hidrogeno, alquilo C1-6, y arilo, que pueden estar opcionalmente sustituidos con 1 a3 sustituyentes seleccionados entre alquilo C1-6, arilo, heteroarilo o halo; R6 se selecciona independientemente entre hidrogeno, alquilo C1-6, arilo, OR11, halo, y NR11; donde el alquilo o arilo puede estar opcionalmente sustituido con 1 a 3 sustituyentes seleccionados entre alquilo C1-6, arilo, heteroarilo o halo; R7 se selecciona independientemente entre hidrogeno, OH, NR112, nitro, CN, amida, carboxilo, alcoxi C1-7, alquilo C1-7, haloalquilo C1-7, haloalquiloxi C1-7, hidroxialquilo C1-7, alquenilo C1-7, alquilC1-7-C(=O)O-, alquilC1-7-C(=O)-, alquinilo C1-7, grupo halo, amida, hidroxialcoxi, -NR11SO2, -SO2NR11, alquilC1-7-NR11SO2-, alquilC1-7-SO2NR11-, alquilC1-7-sulfonilo, alquilC1-7-amino y dialquilC1-7-amino; R10 se selecciona independientemente entre arilo, y heterociclilo, que pueden estar opcionalmente sustituidos; R11 se selecciona independientemente entre hidrogeno, alquilo C1-6 sin sustituir o sustituido, y arilo sin sustituir o sustituido; L2 se selecciona entre un enlace, alquileno C1-4, alquinilo C1-4, alquenilo C1-4, -O-, -S-, -NH-, -C(=O)NH-, -NHC(=O)-, -NHC(=O)NH-, -SO2NH-, -NHSO2-, -SO2-, -C(=O)- y -C(=O)O-; R12 se selecciona entre: heteroarilo sustituido o sin sustituir, heterociclilo sustituido o sin sustituir, arilo sustituido o sin sustituir, y cicloalquilo C3-8 sustituido o sin sustituir; m es 0, 1 o 2; n se selecciona independientemente entre 0, 1, 2, 3 y 4; p es 0, 1 o 2, con la condicion de que la suma de las variables m y p no sea mayor de 2; q es 1, 2, 3, o 4; o un estereoisomeros o una sal farmacéuticamente aceptable del mismo.
ARP060104989A 2005-11-23 2006-11-14 Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac) AR057579A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73932405P 2005-11-23 2005-11-23

Publications (1)

Publication Number Publication Date
AR057579A1 true AR057579A1 (es) 2007-12-05

Family

ID=37811669

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104989A AR057579A1 (es) 2005-11-23 2006-11-14 Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)

Country Status (17)

Country Link
US (4) US7544695B2 (es)
EP (1) EP1954698B1 (es)
JP (1) JP4921485B2 (es)
KR (1) KR20080069630A (es)
CN (1) CN101312976A (es)
AR (1) AR057579A1 (es)
AT (1) ATE434618T1 (es)
AU (1) AU2006318773B2 (es)
BR (1) BRPI0618904A2 (es)
CA (1) CA2629777C (es)
DE (1) DE602006007482D1 (es)
DO (1) DOP2006000260A (es)
NO (1) NO20082823L (es)
PE (1) PE20071084A1 (es)
RU (1) RU2008125068A (es)
TW (1) TW200804381A (es)
WO (2) WO2007061880A1 (es)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
EP1874755A4 (en) 2005-04-20 2010-04-28 Merck Sharp & Dohme BENZOTHIOPHENE-hydroxamic acid derivatives
EP1874294A4 (en) 2005-04-20 2010-12-01 Merck Sharp & Dohme HYDROXAMIC ACID DERIVATIVES OF BENZOTHIOPHENE WITH CARBAMATE, UREA, AMIDE AND SULFAMIDE SUBSTITUTIONS
JP2008546793A (ja) 2005-06-24 2008-12-25 メルク エンド カムパニー インコーポレーテッド 修飾マロン酸誘導体
AR057579A1 (es) 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
US20070213311A1 (en) * 2006-03-02 2007-09-13 Yun-Long Li Modulators of 11-beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
WO2007103719A2 (en) * 2006-03-03 2007-09-13 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
CA2648804C (en) * 2006-04-07 2014-05-27 Methylgene Inc. Benzamide derivatives as inhibitors of histone deacetylase
US20080247964A1 (en) * 2006-05-08 2008-10-09 Yuelian Xu Substituted azaspiro derivatives
CA2651681A1 (en) * 2006-05-18 2007-11-29 Merck & Co., Inc. Aryl-fused spirocyclic compounds
US8030344B2 (en) 2007-03-13 2011-10-04 Methylgene Inc. Inhibitors of histone deacetylase
CL2008001839A1 (es) 2007-06-21 2009-01-16 Incyte Holdings Corp Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
FR2920774B1 (fr) 2007-09-06 2009-10-30 Galderma Res & Dev Nouveaux derives de n-phenul acatamide, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contentant
ES2569215T3 (es) 2007-09-10 2016-05-09 Boston Biomedical, Inc. Un nuevo grupo de inhibidores de la ruta de Stat3 e inhibidores de la ruta de las células madre del cáncer
WO2009037542A2 (en) * 2007-09-20 2009-03-26 Glenmark Pharmaceuticals, S.A. Spirocyclic compounds as stearoyl coa desaturase inhibitors
US20100317679A1 (en) * 2007-09-21 2010-12-16 Ligand Pharmaceuticals, Inc. Substituted aryl-fused spirocyclic amines
US8614324B2 (en) * 2008-10-31 2013-12-24 Pain Therapeutics, Inc. Filamin A binding anti-inflammatory and analgesic
US8653068B2 (en) * 2009-10-30 2014-02-18 Pain Therapeutics, Inc. Filamin A binding anti-inflammatory and analgesic
US9340558B2 (en) 2007-11-02 2016-05-17 Pain Therapeutics Inc. Filamin a binding anti-inflammatory and analgesic
SG189775A1 (en) 2008-04-11 2013-05-31 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
EP2311840A1 (en) 2009-10-13 2011-04-20 DAC S.r.l. Spirocyclic derivatives as histone deacetylase inhibitors
EP2110377A1 (en) * 2008-04-15 2009-10-21 DAC S.r.l. Spirocyclic derivatives as histone deacetylase inhibitors
EP2320897B1 (en) 2008-08-29 2014-01-15 Treventis Corporation Compositions and methods of treating amyloid disease
WO2010028192A1 (en) 2008-09-03 2010-03-11 Repligen Corporation Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors
US8580808B2 (en) * 2009-10-30 2013-11-12 Pain Therapeutic, Inc. Filamin A-binding anti-inflammatory analgesic
WO2010051497A1 (en) * 2008-10-31 2010-05-06 Pain Therapeutics, Inc. Filamin a binding anti-inflammatory and analgesic
CN101397295B (zh) * 2008-11-12 2012-04-25 深圳微芯生物科技有限责任公司 作为组蛋白去乙酰化酶抑制剂的2-吲哚满酮衍生物、其制法和用途
WO2010141817A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
WO2010143803A2 (en) * 2009-06-08 2010-12-16 Industry Foundation Of Chonnam National University New nicotinamide derivatives with anti-androgen effects, processes of preparing, and antiandrogens comprising the same
US8580809B2 (en) * 2009-10-30 2013-11-12 Pain Therapeutics, Inc. Filamin A-binding anti-inflammatory analgesic
WO2011140425A1 (en) 2010-05-06 2011-11-10 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
RU2634900C2 (ru) 2011-02-02 2017-11-08 Вертекс Фармасьютикалз Инкорпорейтед Спироциклические пирролопиразин(пиперидин)амиды в качестве модуляторов ионных каналов
AU2012217616B2 (en) 2011-02-18 2017-03-02 Vertex Pharmaceuticals Incorporated Chroman - spirocyclic piperidine amides as modulators of ion channels
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
PT2680694T (pt) 2011-02-28 2019-03-14 Biomarin Pharm Inc Inibidores de histona deacetilase
EP2686325B1 (en) 2011-03-14 2016-12-14 Vertex Pharmaceuticals Incorporated Morpholine-spirocyclic piperidine amides as modulators of ion channels
EP2686298B1 (de) 2011-03-16 2018-05-09 Creative Therapeutics GmbH Substituierte diphenylderivate
WO2012126275A1 (zh) * 2011-03-18 2012-09-27 山东亨利医药科技有限责任公司 含有螺环的二氢吡唑类化合物
EP2557075A1 (de) 2011-08-09 2013-02-13 Trin Therapeutics GmbH Neue Triazenverbindungen zur Behandlung von Krebs
US8987316B2 (en) 2011-09-23 2015-03-24 DoubleHill GmbH Isocyanate and isothiocyanate compounds for cancer treatment
EP2882428B1 (en) 2012-07-13 2019-01-16 Pain Therapeutics, Inc. A method of inhibiting tau phosphorylation
EP2872899B1 (en) 2012-07-13 2018-07-11 Pain Therapeutics, Inc. Alzheimer's disease assay in a living patient
BR112015023399A8 (pt) 2013-03-15 2019-12-03 Biomarin Pharm Inc inibidores de hdac, seu uso e composição farmacêutica
EP2970266B1 (en) 2013-03-15 2018-01-31 Epizyme, Inc. 1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof
EA201591532A1 (ru) 2013-03-15 2016-03-31 Эпизим, Инк. Ингибиторы carm1 и их применение
US9346802B2 (en) 2013-03-15 2016-05-24 Epizyme, Inc. CARM1 inhibitors and uses thereof
BR112015025347A2 (pt) 2013-04-09 2017-07-18 Boston Biomedical Inc 2-acetil-nafto [2-3-b] furan-4,9-diona para uso no tratamento do câncer
UA119247C2 (uk) 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
US9433604B2 (en) 2013-10-08 2016-09-06 Pain Therapeutics Inc. Method for inhibiting growth of cancer cells
US9636298B2 (en) 2014-01-17 2017-05-02 Methylgene Inc. Prodrugs of compounds that enhance antifungal activity and compositions of said prodrugs
JO3517B1 (ar) * 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
ES2850999T3 (es) * 2014-03-14 2021-09-02 Raqualia Pharma Inc Derivados de azaespiro como antagonistas de TRPM8
EA201790185A1 (ru) 2014-07-15 2017-07-31 Грюненталь Гмбх Замещенные азаспиро(4.5)декановые производные
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環（４．５）癸烷衍生物
EP3194398A4 (en) * 2014-09-17 2018-02-21 Epizyme, Inc. Salts, co-crystals, amorphous forms, and crystalline forms of a co-activator-associated arginine methyltransferase 1 (carm1) inhibitor
CN107835810A (zh) 2014-12-12 2018-03-23 瑞格纳西制药有限公司 作为hdac1/2抑制剂的哌啶衍生物
CR20170326A (es) 2014-12-19 2017-08-22 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipéptidos que contienen regiones fc variantes, y métodos de uso
US10183934B2 (en) 2015-02-02 2019-01-22 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
CN114057765A (zh) 2015-02-02 2022-02-18 瓦洛健康股份有限公司 作为hdac抑制剂的3-芳基-4-酰氨基-二环[4,5,0]异羟肟酸
AU2016233568A1 (en) 2015-03-13 2017-10-05 Forma Therapeutics, Inc. Alpha-cinnamide compounds and compositions as HDAC8 inhibitors
SG11201707911VA (en) * 2015-04-03 2017-10-30 Kalyra Pharmaceuticals Inc Spirocyclic compounds
MX2017017127A (es) * 2015-07-02 2018-03-09 Biomarin Pharm Inc Inhibidores de histona desacetilasas.
WO2017005583A1 (en) * 2015-07-03 2017-01-12 F. Hoffmann-La Roche Ag Triaza-spirodecanones as ddr1 inhibitors
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
US20180194769A1 (en) 2015-07-06 2018-07-12 Rodin Therapeutics, Inc. Hetero-halo inhibitors of histone deacetylase
FI3429591T3 (fi) 2016-03-16 2023-06-15 Kura Oncology Inc Substituoituja tieno[2,3-d]pyrimidiinijohdannaisia meniini-mll:n estäjinä ja käyttömenetelmiä
CN105601617B (zh) * 2016-03-24 2019-02-22 山东省科学院生物研究所 一种邻二氮杂环化合物及其制备方法与应用
WO2017218950A1 (en) 2016-06-17 2017-12-21 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors
KR20230079499A (ko) 2016-08-05 2023-06-07 추가이 세이야쿠 가부시키가이샤 Il-8 관련 질환의 치료용 또는 예방용 조성물
CN106397575A (zh) * 2016-10-20 2017-02-15 上海懿贝瑞生物医药科技有限公司 一种具有胞外组蛋白毒性抑制作用的多肽制备方法及用途
WO2018102427A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
TW201829381A (zh) * 2016-12-22 2018-08-16 美商拜奧馬林製藥公司 組蛋白脫乙醯基酶抑制劑
AU2018207402B2 (en) 2017-01-11 2023-09-28 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
US10646464B2 (en) 2017-05-17 2020-05-12 Boston Biomedical, Inc. Methods for treating cancer
SG11202000970WA (en) 2017-08-07 2020-02-27 Rodin Therapeutics Inc Bicyclic inhibitors of histone deacetylase
TW201920170A (zh) 2017-09-20 2019-06-01 美商庫拉腫瘤技術股份有限公司 經取代之menin-mll 抑制劑及使用方法
CN110156674A (zh) * 2018-02-13 2019-08-23 中国科学院上海有机化学研究所 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物
WO2020063618A1 (zh) * 2018-09-27 2020-04-02 深圳微芯生物科技股份有限公司 具有吲哚胺-2,3-双加氧酶抑制活性的喹啉衍生物
WO2020096916A2 (en) * 2018-11-08 2020-05-14 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase useful for the treatment or prevention of hiv infection
WO2023076133A1 (en) * 2021-10-27 2023-05-04 Merck Sharp & Dohme Llc Spirotricycle ripk1 inhibitors and methods of uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700811A (en) * 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5369108A (en) * 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
HUP9900028A3 (en) * 1995-10-17 1999-11-29 Astrazeneca Ab Pharmaceutically active quinazoline compounds, their production, use thereof and medicament containing them
US5833102A (en) * 1996-11-13 1998-11-10 Jacobson; Jeffery Thomas Portable vehicle-mounted support
JPH11335375A (ja) 1998-05-20 1999-12-07 Mitsui Chem Inc ヒストン脱アセチル化酵素阻害作用を有するベンズアミド誘導体
US6511990B1 (en) * 1999-09-08 2003-01-28 Sloan-Kettering Institute For Cancer Research Class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
AU1244001A (en) 1999-10-27 2001-05-08 Cor Therapeutics, Inc. Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation
MXPA02005196A (es) 1999-11-23 2003-09-22 Methylgene Inc Inhibidores de deacetilasa de histona.
JP3558079B2 (ja) 2001-03-19 2004-08-25 小野薬品工業株式会社 トリアザスピロ［５．５］ウンデカン誘導体およびそれらを有効成分とする薬剤
US6784173B2 (en) * 2001-06-15 2004-08-31 Hoffmann-La Roche Inc. Aromatic dicarboxylic acid derivatives
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
BR0212510A (pt) 2001-09-14 2004-08-24 Methylgene Inc Inibidor de histona desacetilase, composto e composição
US7868204B2 (en) * 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
EP1485370B1 (en) 2002-03-13 2009-03-04 Janssen Pharmaceutica N.V. Amino-derivatives as novel inhibitors of histone deacetylase
US7446109B2 (en) 2002-03-13 2008-11-04 Janssen Pharmaceutica N.V. Carbonylamino-derivatives as novel inhibitors of histone deacetylase
AU2003218738B2 (en) 2002-03-13 2009-01-08 Janssen Pharmaceutica N.V. Sulfonyl-derivatives as novel inhibitors of histone deacetylase
TWI319387B (en) 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
GB0209715D0 (en) 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
KR20050057408A (ko) 2002-09-18 2005-06-16 오노 야꾸힝 고교 가부시키가이샤 트리아자스피로[5.5]운데칸 유도체 및 이를 유효 성분으로하는 약제
EP1641458A2 (en) 2002-12-27 2006-04-05 Schering Aktiengesellschaft Pharmaceutical combinations of phthalazine vegf inhibitors and benzamide hdac inhibitors
AU2004276337B2 (en) 2003-09-24 2009-11-12 Methylgene Inc. Inhibitors of histone deacetylase
IN2003CH00929A (es) * 2003-11-13 2008-10-06
KR101258504B1 (ko) 2004-03-26 2013-04-26 메틸진 인코포레이티드 히스톤 데아세틸라제의 억제제
US7345043B2 (en) * 2004-04-01 2008-03-18 Miikana Therapeutics Inhibitors of histone deacetylase
AR057579A1 (es) 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)

Also Published As

Publication number Publication date
BRPI0618904A2 (pt) 2016-09-13
US8686020B2 (en) 2014-04-01
TW200804381A (en) 2008-01-16
US20090209566A1 (en) 2009-08-20
WO2007061978A1 (en) 2007-05-31
US7834026B2 (en) 2010-11-16
EP1954698B1 (en) 2009-06-24
CA2629777A1 (en) 2007-05-31
US20110098268A1 (en) 2011-04-28
CN101312976A (zh) 2008-11-26
PE20071084A1 (es) 2008-01-10
KR20080069630A (ko) 2008-07-28
JP2009516743A (ja) 2009-04-23
CA2629777C (en) 2011-08-16
WO2007061880A1 (en) 2007-05-31
EP1954698A1 (en) 2008-08-13
US8349825B2 (en) 2013-01-08
JP4921485B2 (ja) 2012-04-25
US7544695B2 (en) 2009-06-09
US20070117824A1 (en) 2007-05-24
RU2008125068A (ru) 2009-12-27
NO20082823L (no) 2008-08-19
ATE434618T1 (de) 2009-07-15
AU2006318773B2 (en) 2012-03-22
DE602006007482D1 (de) 2009-08-06
AU2006318773A1 (en) 2007-05-31
DOP2006000260A (es) 2007-06-30
US20130131041A1 (en) 2013-05-23

Similar Documents

Publication Publication Date Title
AR057579A1 (es) Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
ECSP088762A (es) Tratamiento del dolor
WO2007136605A3 (en) Aryl-fused spirocyclic compounds
BRPI0818193B8 (pt) composto, composição farmacêutica, e, uso de um composto
AR076707A1 (es) Derivados amino-propionicos sustituidos como inhibidores de neprilisina
WO2007087129A3 (en) Fluorinated arylamide derivatives
WO2007087130A3 (en) Hydroxyalkylarylamide derivatives
AR076706A1 (es) Derivados aminobutiricos sustituidos como inhibidores de neprilisina
AR085004A1 (es) Inhibidores selectivos de glicosidasas y usos de los mismos
WO2007127137A3 (en) Disubstituted aniline compounds
UY29869A1 (es) Compuestos de benzamida
BR112012018246A2 (pt) compostos de amida reversa como inibidores de proteína desacetilase e métodos de uso destes
AR055303A1 (es) Derivados de triazol sustituidos como antagonistas de oxitocina, composicion farmaceutica y uso del compuesto para preparar un medicamento
AR038814A1 (es) Compuestos de 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-ona y uso en la fabricacion de medicamentos
AR101177A1 (es) Inhibidores de la syk
AR049399A1 (es) Difenilimidazopirimidina e -imidazol aminas como inhibidores de b-secretasa y metodo de obtencion de los mismos
AR070828A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
PE20090648A1 (es) Compuestos para el tratamiento de la hepatitis c
WO2008010985A3 (en) Phosphorus derivatives as histone deacetylase inhibitors
AR082619A1 (es) Inhibidores del virus de la hepatitis c
AR068466A1 (es) Cianoisoquinolina
CO6321241A2 (es) Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp)
AR043181A1 (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxiptamina-6
AR064253A1 (es) Compuestos de biciclocarboxiamida sustituidos composiciones farmaceuticas y una combinacion que los incluye y su uso en fabaricacion de un medicamento para el tratamiento de enfermedades mediadas por la actividad del receptor vr1
AR048001A1 (es) Hidroxi - 6 - fenilantridinas que contienen tio con actividad inhibitoria de pde4 y composiciones farmaceuticas que las contienen para el tratamiento de trastornos respiratorios.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal